Time is running out to share your #MyelomaTreatment perspectives!
If you or a loved one are affected by myeloma, your input is valuable. Thank you so much to the 800+ people who have already completed the survey.

Survey closes: 14 April
mpe.getfeedback.com/treatmentsurve…

Explore the MPE factsheet on teclistamab:
🧬EMA-approved bispecific antibody for refractory myeloma.
📊High response rates with a median response duration of 18.4 months.
💉Administered via subcutaneous injections with step-up dosing.
Learn more here: mpeurope.org/factsheets/tec…

Myeloma Patients Europe’s (MPE) patient evidence department is undertaking its latest project on how patients feel about how, where and when they receive their myeloma treatments. Multiple Myeloma Ireland is supporting this research which also explores

The EU Health - #HealthUnion 's recent online consultation on the #HTARegulation draft is a milestone for EU collaboration.
📝 MPE provided feedback that recommends stronger #PatientInvolvement and clearer timelines for engagement.

💬 Read more about it here: mpeurope.org/2024/04/08/mpe…

Get involved in MPE activities! Whether you are passionate about advocacy, sharing experiences or expanding your knowledge, our community welcomes you.

Click here for details:mpeurope.org/get-involved-i…

🔍Explore our Q&A on living with AL amyloidosis. You will find information from workability to mental wellbeing, we cover essential topics for navigating life with this rare disease.

Click for details: mpeurope.org/qas/living-wit…

Register for our webinar on 'AL amyloidosis treatment updates and patient experiences'.
🗓️16 April
🕔 17:00 – 18:00 CEST
Dr. Moshe Gatt, the Hebrew University of Jerusalem, Israel, will lead the session and two AL amyloidosis patients will share insights.
mpeurope.org/2024/03/26/sig…

MPE a mis au point une enquête pour explorer le sentiment des patients (et de leurs soignants) sur la manière, le lieu et quand ils reçoivent leurs traitements contre le myélome.

L'enquête de 15 à 20 minutes est disponible ci-dessous en français: mpe.getfeedback.com/treatmentsurvey

Learn all about CAR T-cell therapy with the MPE Q&A!
Discover eligibility criteria, authorised products in the EU, short and long-term side effects, safety measures, precautions and ways caregivers can support you throughout the process.
Read the Q&A here: mpeurope.org/qas/car-t-cell…

📢Join us for the MPE webinar 'AL amyloidosis treatment updates & patient experiences'

🗓️Date: Tuesday, 16 April
🕔Time: 17:00 – 18:00 CEST

Dr. Moshe Gatt will lead the session and two #ALAmyloidosisPatients will share their experience.

🔗Register:mpeurope.org/2024/03/26/sig…

For the latest updates on #myeloma , #ALamyloidosis , and MPE's patient advocacy initiatives, join our official MPE Telegram Channel by clicking the link below! Stay informed and connected with our community.

📲t.me/covid19andmyel…

Snežana´s patient story began unexpectedly as she was diagnosed with high-risk myeloma during a routine checkup, despite not having any symptoms. Since then, she has learned how to balance treatments with everyday activities.

Read more about her here: mpeurope.org/2024/03/25/sne…

Explore our detailed Q&A report comparing myeloma and AL amyloidosis. Learn about their similarities, differences, treatment options and more.

Read now: mpeurope.org/qas/al-amyloid…

Register for our webinar on 'AL amyloidosis treatment updates and patient experiences on new therapies'
🗓Date: Tuesday 16 April
🕔Time: 17:00 – 18:00 CEST
Dr. Moshe Gatt, Haematologist at the Hebrew University of Jerusalem, Israel will lead the session.
mpeurope.org/2024/03/26/sig…

Discover the MPE myeloma CAR-T treatment resource page!
Learn about CAR-T, an innovative form of immunotherapy for myeloma.
Access:
🔍 Q&A's
📑 Factsheets
💬 Webinars and Interviews
🔬 Research Projects

Explore now: mpeurope.org/car-t-cell-the…

Snežana's story is one of resilience and determination in the face of unexpected challenges. After a routine checkup led to her high-risk #MyelomaDiagnosis , she confronted the ups and downs and refuses to let her diagnosis define her life.

Read her story:mpeurope.org/2024/03/25/sne…

If you are a patient organisation, join MPE and be part of the following initiatives!

📣Advocate for patients in policy debates
🤝Raise awareness about myeloma
💪Strengthen your organisation's advocacy efforts
🔬Support research initiatives

mpeurope.org/become-a-mpe-m…

For #YoungMyelomaPatients , the experience involves balancing treatments, careers and professional relationships. Let's support and empower young adults living with myeloma this #MyelomaAwarenessMonth !
mpeurope.org/european-young…

#Myeloma affects people of all ages, including younger adults. This March, we are raising awareness and highlighting resources tailored to their needs.

Learn about the MPE European Young Myeloma Patients Group here: mpeurope.org/european-young…

MPE a mis au point une enquête pour explorer le sentiment des patients (et de leurs soignants) sur la manière, le lieu et quand ils reçoivent leurs traitements contre le myélome.

L'enquête de 15 à 20 minutes est disponible ci-dessous en français: mpe.getfeedback.com/treatmentsurvey